cystic fibrosis transmembrane conductance regulator (505-511) has been researched along with 1-methyl-3-isobutylxanthine in 1 studies
Studies (cystic fibrosis transmembrane conductance regulator (505-511)) | Trials (cystic fibrosis transmembrane conductance regulator (505-511)) | Recent Studies (post-2010) (cystic fibrosis transmembrane conductance regulator (505-511)) | Studies (1-methyl-3-isobutylxanthine) | Trials (1-methyl-3-isobutylxanthine) | Recent Studies (post-2010) (1-methyl-3-isobutylxanthine) |
---|---|---|---|---|---|
17 | 1 | 3 | 5,148 | 5 | 279 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
König, J; Kunzelmann, K; Mall, M; Schreiber, R | 1 |
1 other study(ies) available for cystic fibrosis transmembrane conductance regulator (505-511) and 1-methyl-3-isobutylxanthine
Article | Year |
---|---|
No evidence for inhibition of ENaC through CFTR-mediated release of ATP.
Topics: 1-Methyl-3-isobutylxanthine; Adenosine Triphosphate; Amiloride; Animals; Colon; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cystic Fibrosis Transmembrane Conductance Regulator; Electric Conductivity; Enzyme Inhibitors; Epithelial Sodium Channels; In Vitro Techniques; Mice; Nucleoside-Diphosphate Kinase; Oocytes; Peptide Fragments; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Sodium Channels; Uridine Triphosphate; Xenopus | 2002 |